Drug development

How Long Does It Take to Develop a Drug?

A new drug typically takes 10 to 15 years from discovery to approval. Clinical development alone averages about a decade, and timelines vary widely by disease and drug type.

Key points

  • From early discovery to approval, development commonly takes 10 to 15 years.
  • An industry analysis of 2011–2020 programs found an average of about 10.5 years from the start of Phase 1 to approval.
  • FDA review of an application usually takes about 10 months under standard review, or 6 months under priority review, measured from the 60-day filing date for new molecular entities.
  • Estimates of the cost to bring one new drug to market range from roughly $1 billion to more than $2.5 billion, depending on the method and on whether failed programs and the cost of capital are included.

Developing a new drug is slow. The most commonly cited range from early discovery to approval is 10 to 15 years, and clinical testing in humans accounts for most of that time. The exact figure depends heavily on the disease, the type of drug, and how the trials are designed.

The timeline, stage by stage

An industry analysis published in 2021 by the Biotechnology Innovation Organization (BIO), Informa Pharma Intelligence, and QLS Advisors examined 6,151 successful phase transitions between 2011 and 2020. It found an average of 10.5 years from the start of Phase 1 to regulatory approval. Discovery and preclinical work come before that.

Stage What happens Average duration
Discovery and preclinical Target selection, lead optimization, animal safety studies Several years (varies widely)
Phase 1 First-in-human safety and dosing 2.3 years
Phase 2 Early evidence of effect, dose selection 3.6 years
Phase 3 Large confirmatory trials 3.3 years
Regulatory stage FDA evaluates the application 1.3 years

Clinical and regulatory durations: BIO, Informa Pharma Intelligence, QLS Advisors (2021). Individual programs can be much faster or much slower.

Phase 2 is the longest clinical phase on average. Programs in some disease areas take far longer: the same analysis found average clinical program durations of 12.2 years in urology and 11.5 years in cardiovascular disease.

Why each stage takes so long

Discovery and preclinical work involve many rounds of chemistry and biology. Each round requires making new molecules, testing them, and analyzing the results. Toxicology studies also have fixed durations, because they must expose animals to the drug for long enough to reveal delayed effects.

Clinical trials are limited by how quickly suitable participants can be enrolled and how long it takes for outcomes to appear. A trial measuring blood pressure might produce answers in weeks. A trial measuring whether a drug prevents heart attacks or extends survival may need to follow thousands of participants for years.

Regulatory review follows timelines agreed under the Prescription Drug User Fee Act (PDUFA). For a new molecular entity, the FDA aims to complete a standard review within 10 months of the 60-day filing date, which is about 12 months from submission. For a priority review, the goal is 6 months from the filing date, or about 8 months from submission.

What makes development faster or slower

Factor Effect on timeline
Disease area Chronic conditions with slow-moving outcomes (for example, many neurological diseases) usually need longer trials than conditions with rapid, measurable endpoints.
Unmet need Serious conditions without good treatments may qualify for FDA expedited programs such as Fast Track, Breakthrough Therapy, or Accelerated Approval.
Endpoints Trials that can use a validated surrogate endpoint (such as a lab measurement) can finish sooner than trials that must measure survival or other long-term outcomes.
Patient population Rare diseases can be slow to enroll because few patients exist, even though the trials themselves are small.
Trial design Seamless Phase 2/3 or adaptive designs can remove gaps between studies.
Setbacks Clinical holds, safety signals, manufacturing problems, or an FDA Complete Response Letter can add years.

The cost of that time

Long timelines are a major reason drug development is expensive. Published estimates differ because researchers use different data and methods:

  • Wouters, McKee, and Luyten (JAMA, 2020) used public data on drugs approved between 2009 and 2018 and estimated a median of about $985 million and a mean of about $1.3 billion per new drug, including spending on failed trials.
  • DiMasi, Grabowski, and Hansen (Journal of Health Economics, 2016) estimated about $2.6 billion per approved new drug, in 2013 dollars. That figure includes the cost of failures and the cost of capital, meaning the return investors give up while money is tied up for years.

Both estimates include the cost of failed programs, because a company's successful drugs have to pay for the ones that did not work. The more time a program spends in development, the more that cost of capital adds up.

What this means for interpreting milestones

Because development is long and expensive, the timing of a drug's next milestone is often as important as the outcome. When Spectral Genomics publishes development timelines as part of its drug pipeline tracking, we separate:

  • dates that have happened, sourced from registries and regulatory records,
  • dates a company has guided toward, labeled as company-reported, and
  • historical benchmarks for how long similar programs have taken.

A sponsor's projected timeline is a plan, not a fact. Historically, clinical trials frequently take longer than originally planned.

Sources

  1. Biotechnology Innovation Organization, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020 (2021).Industry report
  2. U.S. Food and Drug Administration. PDUFA VII: Fiscal Years 2023–2027 commitment letter.Regulator
  3. Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA. 2020;323(9):844–853.Peer-reviewed
  4. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. Journal of Health Economics. 2016;47:20–33.Peer-reviewed
  5. U.S. Food and Drug Administration. The Drug Development Process.Regulator

This article is for education. It is not medical advice and not investment advice. Figures are drawn from the sources above and describe historical averages, not the prospects of any particular drug. See our editorial standards and disclaimer.